Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Resmed Inc (NY: RMD )

212.08 +28.66 (+15.63%)
Streaming Delayed Price Updated: 11:55 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,225,524
Open 203.02
Bid (Size) 212.07 (2)
Ask (Size) 212.29 (4)
Prev. Close 183.42
Today's Range 201.86 - 218.36
52wk Range 132.24 - 243.52
Shares Outstanding 146,234,244
Dividend Yield 0.91%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday
Via Benzinga
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes
ResMed is the biggest maker of CPAPs in the U.S., and says the growing popularity of weight-loss drugs could help diagnosis rates. 
Via Investor's Business Daily

Performance

YTD
+23.46%
+23.46%
1 Month
+9.22%
+9.22%
3 Month
+13.81%
+13.81%
6 Month
+52.87%
+52.87%
1 Year
-5.29%
-5.29%

More News

Read More
ResMed Analysts Boost Their Forecasts After Better-Than-Expected Earnings
Via Benzinga
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why NYSE:RMD qualifies as a good dividend investing stock.
Via Chartmill
Expert Outlook: ResMed Through The Eyes Of 9 Analysts
Via Benzinga
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
Via Benzinga
Topics Economy
Exposures Interest Rates
RMD Stock Earnings: ResMed Beats EPS, Beats Revenue for Q3 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
Peering Into ResMed's Recent Short Interest
Via Benzinga
Why NYSE:RMD provides a good dividend, while having solid fundamentals.
Via Chartmill
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Via Investor's Business Daily
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
Via The Motley Fool
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
Via Investor's Business Daily
Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years
Via Benzinga
Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy'
Via Benzinga
Uncovering Dividend Opportunities with NYSE:RMD.
Via Chartmill
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
From ResMed Inc.
Via GlobeNewswire
$1000 Invested In ResMed 10 Years Ago Would Be Worth This Much Today
Via Benzinga
ASX : RMD - Resmed Stock Analysis & Elliott Wave Technical Forecast
Via Talk Markets
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
From ResMed Inc.
Via GlobeNewswire
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
From ResMed Inc.
Via GlobeNewswire
Got $1,000? Buy These Hot Growth Stocks Before They Take Off
Via The Motley Fool
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
From ResMed Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.